Plaque rupture and thromboembolism play a major role in atherosclerotic acute syndrome. Experimental studies have demonstrated the potential direct anti-atherosclerotic effects of calcium antagonists. We investigated the in vitro effect of lercanidipine (REC 15/2375), a third-generation, highly lipophilic calcium antagonist on cholesterol metabolism and matrix metalloproteinases secretion in macrophages, two functions that predispose plaques to rupture. Lercanidipine (10 126\u201310 125 M) inhibited cholesterol esterification in macrophagesand reduced cellular free and esterified cholesterol accumulation from acetylated LDL (63%, 62% of control P < 0.05, respectively). In addition, lercanidipine inhibited the release of metalloproteinases i...
BACKGROUND: Most cardiovascular events associated with hypertension are complications of atheroscler...
WOS: 000284731000001PubMed ID: 20709189The antiatherosclerotic effect of lacidipine has been attribu...
Lacidipine, a third generation dihydropyridine calcium antagonist, has demonstrated pronounced anti-...
Atherosclerosis results from multiple factors and involves several mechanisms, including endothelial...
Atherosclerosis is the major form of heart disease in Western countries. Atherosclerosis is a slowly...
1. Cholesterol esterification and accumulation in the arterial wall is a hallmark of atherogenesis. ...
Activated macrophages within the arterial wall secrete matrixdegrading metalloproteinases (MMPs) tha...
Increased expression/activity of matrix metalloproteinases (MMPs), especially MMP-2, plays a role in...
It has been known for some time that calcium antagonists demonstrate antiatherosclerotic activity. T...
Long-acting third-generation dihydropyridine calcium channel blockers (CCBs) improve endothelial dys...
AIM: To evaluate the effect of lacidipine on the major processes of atherogenesis. METHODS: Cell-cul...
Experimental data indicate that calcium antagonists modify cellular lipid metabolism in the arterial...
Several calcium entry blockers have shown an antiatherosclerotic effect both in vitro and in vivo. T...
Abnormal matrix metalloproteinases (MMPs) activity causes cardiovascular diseases. Because hyperglyc...
Calcium channel blocker (CCB’s) are widely used for the treatment of hypertension (HTN) alone or in ...
BACKGROUND: Most cardiovascular events associated with hypertension are complications of atheroscler...
WOS: 000284731000001PubMed ID: 20709189The antiatherosclerotic effect of lacidipine has been attribu...
Lacidipine, a third generation dihydropyridine calcium antagonist, has demonstrated pronounced anti-...
Atherosclerosis results from multiple factors and involves several mechanisms, including endothelial...
Atherosclerosis is the major form of heart disease in Western countries. Atherosclerosis is a slowly...
1. Cholesterol esterification and accumulation in the arterial wall is a hallmark of atherogenesis. ...
Activated macrophages within the arterial wall secrete matrixdegrading metalloproteinases (MMPs) tha...
Increased expression/activity of matrix metalloproteinases (MMPs), especially MMP-2, plays a role in...
It has been known for some time that calcium antagonists demonstrate antiatherosclerotic activity. T...
Long-acting third-generation dihydropyridine calcium channel blockers (CCBs) improve endothelial dys...
AIM: To evaluate the effect of lacidipine on the major processes of atherogenesis. METHODS: Cell-cul...
Experimental data indicate that calcium antagonists modify cellular lipid metabolism in the arterial...
Several calcium entry blockers have shown an antiatherosclerotic effect both in vitro and in vivo. T...
Abnormal matrix metalloproteinases (MMPs) activity causes cardiovascular diseases. Because hyperglyc...
Calcium channel blocker (CCB’s) are widely used for the treatment of hypertension (HTN) alone or in ...
BACKGROUND: Most cardiovascular events associated with hypertension are complications of atheroscler...
WOS: 000284731000001PubMed ID: 20709189The antiatherosclerotic effect of lacidipine has been attribu...
Lacidipine, a third generation dihydropyridine calcium antagonist, has demonstrated pronounced anti-...